title: Lithium and valproate modulate antioxidant enzymes and prevent ouabain-induced oxidative damage in an animal model of mania.
abstract: In this study, we assessed the oxidative stress parameters in rats submitted to an animal model of mania induced by ouabain (OUA), which included the use of lithium (Li) and valproate (VPA). Li and VPA treatment reversed and prevented the OUA-induced damage in these structures, however, this effect varies depending on the brain region and treatment regimen. Moreover, the activity of the antioxidant enzymes, namely, superoxide dismutase (SOD) and catalase (CAT) was found to be increased and decreased, respectively, in the brain of OUA-administered rats. Li and VPA modulated SOD and CAT activities in OUA-subjected rats in both experimental models. Our results support the notion that Li and VPA exert antioxidant-like properties in the brain of rats submitted to animal model of mania induced by ouabain.
authors.affiliation: Laboratory of Neurosciences and National Institute for Translational Medicine (INCT-TM), Postgraduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, 88806-000 Criciúma, SC, Brazil.
authors.forename: Luciano K
authors.initials: LK
authors.lastname: Jornada
authors.forename: Samira S
authors.initials: SS
authors.lastname: Valvassori
authors.forename: Amanda V
authors.initials: AV
authors.lastname: Steckert
authors.forename: Morgana
authors.initials: M
authors.lastname: Moretti
authors.forename: Francielle
authors.initials: F
authors.lastname: Mina
authors.forename: Camila L
authors.initials: CL
authors.lastname: Ferreira
authors.forename: Camila O
authors.initials: CO
authors.lastname: Arent
authors.forename: Felipe
authors.initials: F
authors.lastname: Dal-Pizzol
authors.forename: João
authors.initials: J
authors.lastname: Quevedo
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D018692:Antimanic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000139:chemically induced* / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D001921:Brain / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D002374:Catalase / Q000378:metabolism; D004195:Disease Models, Animal; D004347:Drug Interactions; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D007276:Injections, Intraventricular; D018021:Lithium Chloride / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D010042:Ouabain / Q000009:adverse effects*; D050050:Protein Carbonylation / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D013482:Superoxide Dismutase / Q000378:metabolism; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D014635:Valproic Acid / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D018692:Antimanic Agents; D017392:Thiobarbituric Acid Reactive Substances; D010042:Ouabain; D014635:Valproic Acid; D002374:Catalase; D013482:Superoxide Dismutase; D018021:Lithium Chloride